Background: In humans, there are four known proton-sensing G-Protein-coupled receptors (pH-GPCRs): GPR4 (GPR19), TDAG8 (GPR65, T-cell death-associated gene 8), OGR1 (GPR68, ovarian cancer GPCR1) and G2A (GPR132, G2 accumulation protein).
| INTRODUC TI ON
In 2003, the Human Genome Project has identified 800 receptors with a structure of seven transmembrane α-helices. [1, 2] These heptahelical transmembrane regions are the structural feature of all G-protein-coupled receptors (GPCRs). [2, 3] Each GPCR shows a selectivity to G-proteins that trigger an intracellular pathway after the receptor's activation. [4] More than 300 of the GPCRs are non-olfactory receptors and the target for more than 50% of the drugs currently on the market that act directly or indirectly on GPCRs. [3, 5] Among these (approximately 350) non-olfactory GPCRs, 200 GPCRs were matched with ligands whereas the other 150
GPCRs are orphan GPCRs whose natural ligands still remain to be identified. [5] In humans, there are four known proton-sensing GPCRs: GPR4 (GPR19), TDAG8 (GPR65, T-cell death-associated gene 8), OGR1
(GPR68, ovarian cancer GPCR1) and G2A (GPR132, G2 accumulation protein).
These GPCRs are known to be involved in sensing changes of extracellular proton concentrations in tumors. [3] The tumor microenvironment shows a more acidic extracellular pH (pH e ) than normal tissue (pH dysregulation, inside-out pH gradient), in part due to the altered vasculature of tumors, which leads to hypoxia. Thus, the cells provide ATP via a high level of anaerobic glycolysis (Warburg effect) causing the accumulation of lactic acid, [6] which is then transported to the extracellular space via monocarboxylate transporters (MCT 1+4). [7, 8] Other proteins involved in the pH dysregulation within a tumor are the Na + /H + exchanger 1 (NHE1), the carbonic anhydrases 2,9 and 12 (CA2, CA9, CA12) and the plasma membrane proton pump vacuolar ATPase (V-ATPase). [7, 8] In summary, the majority of tumors exhibit lower pH e (6.2-7.0) and higher pH i (7.2-7.7) compared to normal cells (pH e 7.2-7.4, pH i 6.9-7.2), which is known as reversed (=inside-out) pH gradient (pH e < pH i ). [3, [7] [8] [9] For tumor growth and metastasis, the microenvironmental changes in pH are essential processes. [3, [7] [8] [9] [10] According to Tomura et al [6] and Damaghi et al [11] cancer cells seem to be more resistant and adjusted to extracellular acidification and maintain the pH i within the physiological range to prevent the cells from cytotoxic acid. Thus, acidosis is a common physical hallmark of solid tumors. [12] As mentioned above, the four proton-sensing GPCRs GPR4, TDAG8, OGR1 and G2A sense microenvironmental pH changes.
Initially identified as receptors for lysolipids, however, Ludwig et al [13] found that the GPCRs sense the pH e through histidine residues and that they are activated via a decrease of pH e through the protonation of hydrogen bondings between the histidine residues.
It is known that they are involved in cancer cell proliferation, metastasis, angiogenesis, apoptosis, immune cell function and inflammation, [3, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] but a detailed understanding of the expression of GPCRs and the exact mechanism by which cancer cells sense pH and respond to acidosis still remains unclear.
Although proton-sensing GPCRs are expressed in various tissues, only little is known about their expression in the skin and skin cancer.
In this study, we examine the expression of the proton-sensing GPCRs GPR4, TDAG8, OGR1 and G2A on the following skin cancer types:
Merkel cell carcinoma (MCC), pleomorphic dermal sarcoma (PDS), dermatofibrosarcoma protuberans (DFSP) and atypical fibroxanthoma (AFX).
These investigations may help to gain more insight into the role of proton-sensing GPCRs and extracellular protons concerning proliferation and migration of the above-mentioned skin cancers. Based on these new insights, novel therapies targeting these GPCRs could be revealed in order to inhibit tumor growth.
| MATERIAL S AND ME THODS
For our experiments, we used paraffin-embedded tissue samples (n = 4, exceptions: PDS GPR4/GPR65 n = 5, AFX GPR132 n = 3) from the dermatopathological routine of the Department of Dermatology, University Medical Center Regensburg. An overview of basal data about the patients the samples were taken from can be found in table S1. The following day, the slides were washed three times with PBS. The tissue sections were then incubated with the secondary biotinylated antibody for 30 minutes, they were washed again three times with PBS, then incubated with streptavidin-HRP conjugate for 20 minutes and washed another three times with PBS.
| Immunohistochemistry
Positive-controls were stained with AEC plus (No. K 3469; Dako, Santa Clara, CA, USA) until the requested staining appeared.
Reaction was stopped with distilled water and positive-controls
were counterstained with Mayer's Haemalm (Roth, No. T865.3).
Analog procedure was performed with tissue sections and negative controls.
| Immunofluorescence
Tissues embedded and fixed in paraffin were sectioned and super- 
| RE SULTS
The epidermis served as a reference structure for the assessment of every single tissue sample. Peritumoral lymphocytes and the epithelium of sebaceous glands, sweat glands and vessels appeared positive in every staining. An overview of the results can be found in Table 1 
| GPR4 (GPR19)
Merkel cell carcinomas showed no expression of GPR4 (GPR19).
50% of the DFSP tissue samples were weak or partial positive for the expression of GPR4, the others showed no expression of GPR4. 
| TDAG8 (GPR65)
The evaluation of the TDAG8 expression-profile showed that neither MCC nor DFSP expressed TDAG8 on the surface of tumor cells. 
| OGR1 (GPR68)
It has to be mentioned that both stainings (IHC and IF) of OGR1 
| G2A (GPR132)
Twenty five percentage of the MCCs showed a strong positive expression of G2A (GPR132). The other 75% exhibited a weak positive expression of G2A. 50% of the DFSP tissue samples presented a clearly positive expression of G2A, 25% appeared to be weak or partial positive for G2A and the other 25% showed no expression of G2A. In 66.6%, the AFX showed a strong and in 33.3% a weak positive expression of G2A with an overall stronger expression of G2A on multinuclear giant cells. All PDS exhibited a strong expression of G2A on the surface of the tumor cells.
| D ISCUSS I ON
Here, we have studied the expression of GPCRs GPR4 (GPR19),
TDAG8 (GPR65), OGR1 (GPR68) and G2A (GPR132) on different
types of skin cancer. While MCC and DFSP did not express TDAG8, half of the studied PDS and AFX were strong or at least weak positive, 50% negative for TDAG8, respectively.
A final statement on expression patterns can only be given for four expression profiles: (a) GPR4 is expressed on all AFX and PDS, (b) G2A is clearly expressed on MCC, DFSP, AFX and PDS, (c) GPR4
and TDAG8 are not expressed on MCC, (d) and TDAG8 is not expressed on DFSP. As AFX and PDS are related pathologies, our results show similar expression profiles of GPR4, TDAG8, OGR1 and G2A on AFX and PDS. For any other combination of receptor and skin disease, we found mixed results.
These very inhomogeneous expression profiles might be explained by the current knowledge about the opposing roles of the four proton-sensing GPRCs, even in the same tumors. [3] It is known that the GPCRs GPR4 (GPR19), TDAG8 (GPR65), OGR1
(GPR68) and G2A (GPR132) are activated via protonation [13] and that they are involved in cancer cell proliferation, metastasis, angiogenesis, apoptosis, immune cell function and inflammation-some in a tumor-promoting and some in a tumor-suppressing pattern. [3, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] While an increased GPR4 signalling induced a broad inflammatory response in human vascular endothelial cells, [3, 22] the deficiency of GPR4 impairs the growth of murine tumor allografts. [3, 18] The overexpression of TDAG8 (GPR65) is known to enhance tumor growth in Lewis lung carcinoma cells, [3, 23] but promotes glucocorticoidinduced apoptosis in mouse lymphoma cells. [3, 24] Expression of OGR1 (GPR68) in human ovarian cancer cells enhances the cell adhesion to extracellular matrix, but inhibits cell proliferation and migration [3, 21] and G2A (GPR132) is known to show anti-tumorigenic properties by cell cycle arrest at G2/M stage. [3, 25] However, based on the current state of research the circumstances and conditions that induce pro-tumorigenic or anti-tumorigenic GPCR-activity yet remain unknown.
Taking everything into account, the role of proton-sensing 
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Additional supporting information may be found online in the Supporting Information section at the end of the article. The expression of GRP4 and GPR132 is significantly increased on AFX. There is no expression of GPR65 and GPR68. 
